van Roozendaal C E, Klijn J G, van Ooijen B, Claassen C, Eggermont A M, Henzen-Logmans S C, Foekens J A
Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
Mol Cell Endocrinol. 1995 Apr 28;111(1):1-6. doi: 10.1016/0303-7207(95)03539-j.
Transforming growth factor beta (TGF-beta) is a hormonally regulated growth inhibitor with autocrine and/or paracrine functions in human breast cancer. In vivo, enhanced immunohistochemical staining of extracellular TGF-beta 1 has been detected around stromal fibroblasts in response to the antiestrogen treatment. We have investigated the effects of tamoxifen on the production of TGF-beta by primary human breast fibroblast cultures in serum-free medium. Highly variable levels of mainly latent TGF-beta 1 were detected in conditioned media from both tumor and normal tissue derived fibroblasts. Hydroxy-tamoxifen was shown to increase latent TGF-beta 1 secretion in three of the eight tumor tissue-derived fibroblast cultures. Such effect of hydroxy-tamoxifen was not observed in fibroblast cultures established from normal adjacent breast tissue.
转化生长因子β（TGF-β）是一种在人类乳腺癌中具有自分泌和/或旁分泌功能的激素调节生长抑制剂。在体内，抗雌激素治疗后，已检测到基质成纤维细胞周围细胞外TGF-β1的免疫组化染色增强。我们研究了他莫昔芬对无血清培养基中正常人乳腺成纤维细胞培养物产生TGF-β的影响。在肿瘤组织和正常组织来源的成纤维细胞的条件培养基中检测到主要为潜伏性TGF-β1的高度可变水平。羟基他莫昔芬在八个肿瘤组织来源的成纤维细胞培养物中的三个中显示出增加潜伏性TGF-β1的分泌。在从相邻正常乳腺组织建立的成纤维细胞培养物中未观察到羟基他莫昔芬的这种作用。
